2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2499

Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2502

Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2580

Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2600

Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2300

Tophaceous Gout and the Risk of Mortality: A General Population-Based Study

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2357

Topical Application of Aceclofenac Might NOT Produce a Significant Increase of Blood Pressure in Osteoarthritic Patients – a Continuous Automated Blood Pressure Monitor Study

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2196

Trajectories and Predictors of Fear-Avoidance in Persons with Rheumatoid Arthritis. a Longitudinal Observational Study

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2273

Trans-Ancestral Meta-Analysis Identifies Nine New Loci Associated with Serum Uric Acid Concentrations

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2138

Transcriptional Analysis of Synovial Tissue Reveals Sustained Inflammatory Chemokine Expression Despite Minimal Histopathologic Change in the Destabilization of Medial Meniscus Model of Murine Knee Osteoarthritis

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2455

Transcriptome Profile of Cells Isolated from a CHB Heart Support an Exuberant Inflammatory ⁄Pro-Fibrotic Cascade

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2426

Transcriptomic Analysis of Immune Subsets in Juvenile Dermatomyositis before and after Treatment Identifies Novel Pathways Involved in Pathogenesis

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2131

Transient Receptor Potential Ankyrin 1 (TRPA1) Is Functionally Expressed in Primary Human Osteoarthritic Chondrocytes and Mediates Cartilage Destruction and Joint Pain in the Mia-Model of Osteoarthritis

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2903

Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2785

Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 2470

Treat to Target: Theoretical Agreement Vs Daily Applicability

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].